Literature DB >> 11347833

Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.

G Bacci1, S Ferrari, F Bertoni, P Picci, P Bacchini, A Longhi, D Donati, C Forni, L Campanacci, M Campanacci.   

Abstract

In 510 patients with osteosarcoma of the extremity treated at the authors' institute between March 1983 and June 1995 with different regimens of neoadjuvant chemotherapy, factors that influenced the histologic response were investigated. The rate of total necrosis was not related to the patients' gender, age, site, size of tumor, serum of alkaline phosphatase values, or route of cisplatin administration. The histologic response significantly and independently correlated with the number of drugs administered before surgery and with the histologic subtype of the tumor. According to the number of drugs used, the percentage of total necrosis was 31% for a four-drug regimen, 18% for a three-drug regimen, and only 1.5% for a two-drug regimen. According to the histologic type, the rates of total necrosis were 41% for telangiectatic tumors, 36% for fibroblastic tumors, 15% for osteoblastic tumors, and 3% for chondroblastic tumors. The authors concluded that in neoadjuvant therapy of osteosarcoma, the histologic response to preoperative treatment, which correlates with prognosis, depends on the effectiveness of the chemotherapy regimen and on some features intrinsically inherent to the tumor. These data should be considered when selecting the type of treatment (adjuvant or neoadjuvant) and the combinations of drugs to be used in preoperative treatment of patients with osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11347833     DOI: 10.1097/00003086-200105000-00024

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

1.  Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.

Authors:  Shuier Zheng; Shuhui Zhou; Guanglei Qiao; Qingcheng Yang; Zhichang Zhang; Feng Lin; Daliu Min; Lina Tang; Hongtao Li; Yuanjue Sun; Hui Zhao; Zan Shen; Yang Yao
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.

Authors:  Barbara Rossi; Giovanni Schinzari; Giulio Maccauro; Laura Scaramuzzo; Diego Signorelli; Michele A Rosa; Carlo Fabbriciani; Barone Carlo
Journal:  BMC Musculoskelet Disord       Date:  2010-02-16       Impact factor: 2.362

3.  A preliminary evaluation of limb salvage surgery for osteosarcoma around knee joint.

Authors:  Xing Wu; Zheng-Dong Cai; Zheng-Rong Chen; Zhen-Jun Yao; Guang-Jian Zhang
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

4.  Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases.

Authors:  V Minard-Colin; C Kalifa; J-M Guinebretiere; L Brugieres; J Dubousset; J-L Habrand; G Vassal; O Hartmann
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

5.  Popliteal lymph node metastasis of tibial osteoblastic osteosarcoma.

Authors:  Yalın Dirik; Arda Çınar; Feridun Yumrukçal; Levent Eralp
Journal:  Int J Surg Case Rep       Date:  2014-10-13

6.  The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells.

Authors:  Sudeshna Mukherjee; Subhra Dash; K Lohitesh; Rajdeep Chowdhury
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

7.  Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.

Authors:  Jantine Posthumadeboer; Pim W van Egmond; Marco N Helder; Renée X de Menezes; Anne-Marie Cleton-Jansen; Jeroen A M Beliën; Henk M W Verheul; Barend J van Royen; Gert-Jan J L Kaspers; Victor W van Beusechem
Journal:  Oncotarget       Date:  2012-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.